UPDATES ON MANAGEMENT OF IRRITABLE BOWEL SYNDROME
UPDATES ON MANAGEMENT OF IRRITABLE BOWEL SYNDROME
UPDATES ON MANAGEMENT OF IRRITABLE BOWEL SYNDROME
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Tegaserod• Adverse events reported significantly more oftenwith tegaserod than with placebo were headache(15% vs. 12%) and diarrhea (9% vs. 4%)• A pooled analysis of data from 29 placebo‐controlledtrials identified 13 ischemic events among 11,614patients treated with tegaserod compared with asingle case among 7,013 placebo‐treated patients.The rate of ischemic events was 0.11% in thetegaserod patients versus 0.01% in the placebogroup• Suspended in US market since 2007
Change language